Show simple item record

Authordc.contributor.authorPáez, Isis 
Authordc.contributor.authorPrado, Yalena 
Authordc.contributor.authorUbilla, Carmen G. 
Authordc.contributor.authorZambrano Coloma, Tomás 
Authordc.contributor.authorSalazar, Luis A. 
Admission datedc.date.accessioned2021-05-13T20:19:40Z
Available datedc.date.available2021-05-13T20:19:40Z
Publication datedc.date.issued2020
Cita de ítemdc.identifier.citationPharmaceuticals 2020, 13, 382es_ES
Identifierdc.identifier.other10.3390/ph13110382
Identifierdc.identifier.urihttps://repositorio.uchile.cl/handle/2250/179605
Abstractdc.description.abstractAtorvastatin is extensively used to treat hypercholesterolemia. However, the wide interindividual variability observed in response to this drug still needs further elucidation. Nowadays, the biology of long non-coding RNAs (lncRNAs) is better understood, and some of these molecules have been related to cholesterol metabolism. Therefore, they could provide additional information on variability in response to statins. The objective of this research was to evaluate the effect of atorvastatin on three lncRNAs (lncRNA ARSR: Activated in renal cell carcinoma (RCC) with sunitinib resistance, ENST00000424980; lncRNA LASER: lipid associated single nucleotide polymorphism locus, ENSG00000237937; and lncRNA CHROME: cholesterol homeostasis regulator of miRNA expression, ENSG00000223960) associated with genes involved in cholesterol metabolism as predictors of lipid-lowering therapy performance. Twenty hypercholesterolemic patients were treated for four weeks with atorvastatin (20 mg/day). The lipid profile was determined before and after drug administration using conventional assays. The expression of lncRNAs was assessed in peripheral blood samples by RT-qPCR. As expected, atorvastatin improved the lipid profile, decreasing total cholesterol, LDL-C, and the TC/HDL-C ratio (p < 0.0001) while increasing the expression of lncRNAs ARSR and CHROME (p < 0.0001) upon completion of treatment. LASER did not show significant differences among the groups (p = 0.50). Our results indicate that atorvastatin modulates the expression of cholesterol-related lncRNAs differentially, suggesting that these molecules play a role in the variability of response to this drug; however, additional studies are needed to disclose the implication of this differential regulation on statin response.es_ES
Patrocinadordc.description.sponsorshipComision Nacional de Investigacion Cientifica y Tecnologica (CONICYT) CONICYT FONDECYT 1171765 Direccion de Investigacion of the Universidad de La Frontera DI11-0063 Conicyt -Chile Doctoral Scholarshipes_ES
Lenguagedc.language.isoenes_ES
Publisherdc.publisherMDPIes_ES
Type of licensedc.rightsAttribution-NonCommercial-NoDerivs 3.0 Chile*
Link to Licensedc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/3.0/cl/*
Sourcedc.sourcePharmaceuticalses_ES
Keywordsdc.subjectAtorvastatines_ES
Keywordsdc.subjectEpidrugses_ES
Keywordsdc.subjectlncRNAses_ES
Keywordsdc.subjectLaseres_ES
Keywordsdc.subjectARSRes_ES
Keywordsdc.subjectChromees_ES
Keywordsdc.subjectHypercholesterolemiaes_ES
Títulodc.titleAtorvastatin increases the expression of long non-coding rnas arsr and chrome in hypercholesterolemic patients: A pilot studyes_ES
Document typedc.typeArtículo de revistaes_ES
dcterms.accessRightsdcterms.accessRightsAcceso Abierto
Catalogueruchile.catalogadorcfres_ES
Indexationuchile.indexArtículo de publicación ISI
Indexationuchile.indexArtículo de publicación SCOPUS


Files in this item

Icon

This item appears in the following Collection(s)

Show simple item record

Attribution-NonCommercial-NoDerivs 3.0 Chile
Except where otherwise noted, this item's license is described as Attribution-NonCommercial-NoDerivs 3.0 Chile